These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


333 related items for PubMed ID: 19696634

  • 1. Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients.
    Cooper M, Deering KL, Slakey DP, Harshaw Q, Arcona S, McCann EL, Rasetto FA, Florman SS.
    Transplantation; 2009 Aug 27; 88(4):514-20. PubMed ID: 19696634
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.
    Ortega F, Sánchez-Fructuoso A, Cruzado JM, Gómez-Alamillo JC, Alarcón A, Pallardó L, Morales JM, Oliver J, Guinea G, MYVIDA Study Group.
    Transplantation; 2011 Aug 27; 92(4):426-32. PubMed ID: 21760569
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
    Budde K, Glander P, Diekmann F, Dragun D, Waiser J, Fritsche L, Neumayer HH.
    Transplant Proc; 2004 Mar 27; 36(2 Suppl):524S-527S. PubMed ID: 15041401
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Bilodeau JF, Montambault P, Wolff JL, Lemire J, Masse M.
    Transplant Proc; 2009 Nov 27; 41(9):3683-9. PubMed ID: 19917367
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Impact of dose reductions on efficacy outcome in heart transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil at 12 months post-transplantation.
    Segovia J, Gerosa G, Almenar L, Livi U, Viganò M, Arizón JM, Yonan N, Di Salvo TG, Renlund DG, Kobashigawa JA, ERL 2401 Study Group.
    Clin Transplant; 2008 Nov 27; 22(6):809-14. PubMed ID: 18702660
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects.
    Sabbatini M, Capone D, Gallo R, Pisani A, Polichetti G, Tarantino G, Gentile A, Rotaia E, Federico S.
    Fundam Clin Pharmacol; 2009 Oct 27; 23(5):617-24. PubMed ID: 19656208
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K, Glander P, Krämer BK, Fischer W, Hoffmann U, Bauer S, Grohmann J, Neumayer HH, Arns W.
    Transplantation; 2007 Feb 27; 83(4):417-24. PubMed ID: 17318074
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil.
    Sánchez Fructuoso A, Calvo N, Moreno MA, Giorgi M, Conesa J, Barrientos A.
    Transplant Proc; 2007 Sep 27; 39(7):2194-6. PubMed ID: 17889135
    [Abstract] [Full Text] [Related]

  • 17. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders.
    Darji P, Vijayaraghavan R, Thiagarajan CM, Sharma RK, Subbarao B, Pishardy R, Dakshinamurthy KV, Vijaykumar R, Abraham G, Bhaskar S, Agarwal L, Shah B, Abraham A, John M, Sampathkumar K, Das T, Umesh L, Sundar S, Ballal H, Jasuja S, Saxena S, Saha TK.
    Transplant Proc; 2008 Sep 27; 40(7):2262-7. PubMed ID: 18790208
    [Abstract] [Full Text] [Related]

  • 18. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
    Ciancio G, Burke GW, Gaynor JJ, Roth D, Sageshima J, Kupin W, Tueros L, Hanson L, Rosen A, Ruiz P, Miller J.
    Transplantation; 2008 Jul 15; 86(1):67-74. PubMed ID: 18622280
    [Abstract] [Full Text] [Related]

  • 19. Enteric-coated mycophenolate sodium immunosuppression in renal transplant patients: efficacy and dosing.
    Cooper M, Salvadori M, Budde K, Oppenheimer F, Sollinger H, Zeier M.
    Transplant Rev (Orlando); 2012 Oct 15; 26(4):233-40. PubMed ID: 22863029
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 17.